W. Gusenleitner

Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age.

B. Resch, W. Müller, A. Pasnocht, 2005, The Journal of infection.

Procalcitonin and interleukin‐6 in the diagnosis of early‐onset sepsis of the neonate

W. Müller, B. Resch, W. Gusenleitner, 2003, Acta paediatrica.

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks

J. Haas, W. Müller, B. Resch, 2006, European Journal of Clinical Microbiology and Infectious Diseases.

Risk of concurrent bacterial infection in preterm infants hospitalized due to respiratory syncytial virus infection

B. Resch, W. Mueller, W. Gusenleitner, 2007, Acta paediatrica.

Epidemiology of respiratory syncytial virus infection in Southern Austria.

B. Resch, W. Müller, W. Gusenleitner, 2000, The Pediatric infectious disease journal.

The Impact of Respiratory Syncytial Virus Infection: A Prospective Study in Hospitalized Infants Younger than 2 Years

W. Müller, B. Resch, W. Müller, 2002, Infection.

Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.

B. Resch, M. Nuijten, W. Wittenberg, 2008, Clinical therapeutics.

Procalcitonin, interleukin-6, C-reactive protein and leukocyte counts in infants with bronchiolitis.

B. Resch, W. Gusenleitner, W. Müller, 2003, The Pediatric infectious disease journal.

THE RISK OF RESPIRATORY SYNCYTIAL VIRUS–RELATED HOSPITALIZATIONS IN PRETERM INFANTS OF 29 TO 35 WEEKS’ GESTATIONAL AGE

Bernhard Resch, S. Burdach, J. Liese, 2006, The Pediatric infectious disease journal.